Organogenesis of kidney and endocrine pancreas: The window opens

Marc R. Hammerman
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Hammerman, Marc R., "Organogenesis of kidney and endocrine pancreas: The window opens."
https://digitalcommons.wustl.edu/open_access_pubs/2543

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Organogenesis Forum

Organogenesis of Kidney and Endocrine Pancreas

The Window Opens

Marc R. Hammerman

Correspondence to: Marc R. Hammerman; George M. O’Brian Center for Kidney Disease Research; Renal Division, Box 8126; Department of Medicine; Washington University School of Medicine; 660 S. Euclid Avenue; St. Louis, Missouri 63110 USA; Tel.: 314.362.8233; Fax: 314.362.8237; Email: mhammerm@wustl.edu

Original manuscript submitted: 10/11/07
Manuscript accepted: 12/04/07

Previously published online as an Organogenesis E-publication:
http://www.landesbioscience.com/journals/organogenesis/article/5382

KEY WORDS
β-cell, chronic kidney disease, diabetes mellitus, non-human primates, transplantation, xenotransplantation

ABBREVIATIONS
APC antigen presenting cell
E embryonic day
ES embryonic stem cell
GFR glomerular filtration rate
MHC major histocompatibility complex
NOD-SCID nonobese diabetic severe combined immunodeficient
PAH P-aminohippurate
SLA swine leukocyte antigen
STZ streptozotocin
UV urine volume

ACKNOWLEDGEMENTS
See page 65.

NOTE
Edited transcripts of research conferences sponsored by Organogenesis and the Washington University George M. O’Brien Center for Kidney Disease Research (P30 DK079333) are published in Organogenesis. These conferences cover organogenesis in all multicellular organisms including research into tissue engineering, artificial organs and organ substitutes and are participated in by faculty at Washington University School of Medicine, St. Louis Missouri, USA.

ABSTRACT

Growing new organs in situ by implanting developing animal organ primordia (organogenesis) represents a novel solution to the problem of limited supply for human donor organs that offers advantages relative to transplanting embryonic stem (ES) cells or xenotransplantation of developed organs. Successful transplantation of organ primordia depends on obtaining them at defined windows during embryonic development within which the risk of teratogenicity is eliminated, growth potential is maximized, and immunogenicity is reduced. We and others have shown that renal primordia transplanted into the mesentery undergo differentiation and growth, become vascularized by blood vessels of host origin, exhibit excretory function and support life in otherwise anephric hosts. Renal primordia can be transplanted across isogenic, allogeneic or xenogeneic barriers. Pancreatic primordia can be transplanted across the same barriers undergo growth, and differentiation of endocrine components only and secrete insulin in a physiological manner following mesenteric placement. Insulin-secreting cells originating from embryonic day (E) 28 (E28) pig pancreatic primordia transplanted into the mesentery of streptozotocin-diabetic (type 1) Lewis rats or ZDF diabetic (type 2) rats or STZ-diabetic rhesus macaques engraft without the need for host immune-suppression. Our findings in diabetic macaques represent the first steps in the opening of a window for a novel treatment of diabetes in humans.

INTRODUCTION

Dr. Marc R. Hammerman: I am pleased to be able to deliver the inaugural Organogenesis Forum lecture. I am going to speak about organogenesis of the kidney and endocrine pancreas. The term ‘organogenesis’ has a number of definitions as reflected by the wide range of subject matter represented in Organogenesis, the journal. For purposes of this lecture, what I mean by ‘organogenesis’ is a novel technology for growing new organs in situ from transplanted embryonic organ primordia, in the development of which we and a number of other laboratories around the world are engaged.1

Previously, we have reviewed why the timing of primordia retrieval from embryos is important for organogenesis. In fact, there are ‘windows of opportunity’ for teratogenesis-free differentiation, vascularization and reduction of immunogenicity post-transplantation.1 Recently, we have generated data that provide the basis for what, to our knowledge, is the first published report of organogenesis in non-human primates.2 Since the use of non-human primates is a key intermediate step towards the employment of virtually any transplantation technology to replace kidney or endocrine pancreas in humans, our manuscript reflects the opening of a clinical window for organogenesis.2

ORGANGENESIS OF KIDNEY

A shortage of human donor organs limits transplantation therapy for end-stage renal disease. We and others have suggested that theoretical strategies for kidney replacement therapies of the future include those listed in Figure 1: (1) the use of human ES cells; or (2) the use renal-specific precursors obtained from developed human kidneys (‘adult’ renal stem cells) to grow a new kidney; (3) therapeutic cloning; (4) xenotransplantation of developed animal kidneys to humans; (5) transplantation of differentiated kidney cells in lieu of whole kidneys (cell therapies); and (6) generation of new kidneys in situ from embryonic primordia (renal organogenesis).3

The design of strategies to coax ES cells or ‘adult’ stem cells into generating a functional kidney is going to be a very difficult task. This is because renal anatomy is so
complex and renal function requires the precise integration in three
dimensions of a large number of highly specialized cells vascularized
at least in part from outside of the organ.5 ‘Close’ is not good enough
to make a functioning kidney. Rather, renal ultrastructure must be
perfect to permit glomerular filtration and tubular secretion and
reabsorption. Because the kidney is so complicated I don’t think ES
or ‘adult’ stem cells are good starting material for whole renal organ
replacement.

Organ formation in human embryos begins several weeks after
implantation. At the present time, in the USA there is considerable
controversy about the generation of human ES cells from fertilized
ova. I don’t believe that it will ever be acceptable to clone and
implant human embryos to the point of organ formation, effectively
excluding this sort of therapeutic cloning as an organ-replacement
therapy.5 Excluding ES and ‘adult’ stem cells and therapeutic
cloning from my list, we are left with xenotransplantation of whole
kidneys, renal cell therapies or organogenesis as theoretical means
by which renal function can be recapitulated in lieu of human
allotransplantation (Fig. 1).

The use of pig kidneys instead of human organs makes sense
because adult pigs and humans are the same size and weight and
have almost identical renal function.4 Unfortunately, the use of pig
kidneys in humans is not a viable option because of humoral rejec-
tion that occurs post-transplantation of vascularized pig organs into
old-world primates. Humoral rejection is complement-mediated and
results in large part from the binding of pre-formed circulating anti-
bodies directed against galactose-α,1,3-galactose, an antigen present
on vascular endothelium of most mammals, but not old world
primates and humans.

The latter lack an enzyme α(1,3-galactosyl-transferase) required
for galactose-α,1,3-galactose antigen formation.4,6 Humoral rejection
of pig kidneys transplanted into non-human primates, can be prevented by using kidneys from transgenic swine that
express an enzyme on their vascular endothelium that deactivates
complement, human decay accelerating factor5 or in which the
gene for α,1,3-galactosyl-transferase is deleted.6 However, the
intensity of cellular rejection of kidney transplants from such
transgenic swine is such that the immune suppressive regimens
required for engraftment in primate hosts result in complications
that could never be tolerated in humans.5,6

Renal cell therapy of sorts has been carried out via implantation
of sectioned2 or whole embryos into developing kidneys of various
species including mice,17 rats,18 hamsters,19 primates and humans.20

In contrast to what occurs after implantation in renal paren-
chyma or beneath the renal capsule, renal primordia transplanted
into a host rodent’s fold of mesentery undergo differentiation and
growth in hosts (renal organogenesis) that is not confined
anatomically.8–10 We and others11,12 have shown experimentally
that growth is enhanced if one of the host’s kidneys is removed
at the time of implantation, and that timing of renal primordia
retrieval is important [embryonic day (E)15 works best for trans-
planted rat primordia].13 If implanted into an adult rat with its
ureteric bud attached, the renal primordium enlarges and becomes
kidney-shaped within three weeks.8 The ureteric bud differenti-
ates into a ureter that can be Anastomosed to the ureter of the host
(ureteroureterostomy).8,9,13–16 Ureteroureterostomy turns out to be a
key procedure for preserving the function of transplanted primordia.
This is because the ureter must be freed from adhesions that often
form as primordia develop in the mesentery. The adhesions obstruct
the ureteric bud and prevent excretion of glomerular/tubular filtrate
into the mesentery. As is the case for obstructed native kidneys
during embryogenesis16 or for renal primordia implanted in renal
parenchyma or beneath the renal capsule,7,8 the obstructed mesen-
teric transplant does not undergo normal renal differentiation,
but rather atrophies and becomes fibrotic.16 Ureteroureterostomy
preserves urine flow as the transplant differentiates. In our hands
(rat-to-rat) it is not possible before 17 days post-transplantation
because the ureter of the transplant is too friable. If uretero-
ureterostomy is not performed by 21 days post-transplantation,
obstruction results. Therefore this procedure must be performed
between 17–21 days after transplantation of metanephroi from
rat embryos into adult rats if optimal differentiation is to occur.16
We have transplanted as many as four metanephroi at the same
time (rat to rat) each of which undergoes growth and development
in the mesentery. In our hands only one ureteroureterostomy is
possible in the rat because of the small size of transplant and host
ureters.16 However Marshall et al. are able to connect ureters from
two transplants into the ureter of a host rat kidney.13–15

In contrast to transplanted developed kidneys that undergo acute
rejection post transplantation into non-immunosuppressed hosts,8
rat renal primordia differentiate into small, but ultrastructurally
normal kidneys after allotransplantation in the mesentery. The
new kidneys become vascularized via arteries that originate from the
superior mesenteric artery of hosts and veins that originate from the
host mesentery.14 Developed renal primordia produce urine that is
excreted via the bladder following ureteroureterostomy between
transplant and host. Levels of renal function in transplanted renal
primordia [glomerular filtration rate (GFR)] can be determined by
measuring inulin clearance in otherwise anephric rats. In our initial
experiments GFRs were very low.9 However, incubation of renal
primordia with growth factors prior to implantation increased GFRs
more than 100-fold compared to those in rats with non growth
factor-incubated renal primordia implanted concurrently. GFRs in
growth factor treated renal primordia are about 6% of normal.14
Others have reported even higher levels of GFR in rat-to-rat trans-
plants.9 Renal plasma flow can be measured in transplanted renal
primordia by calculating P-aminohippurate (PAH) clearances. The
ratio of GFR/PAH clearance (filtration fraction) is 0.6, comparable
to filtration fractions measured in rats with reduced renal function.
Urine flow rates in transplanted rats are about 12% of the inulin
clearance (GFR) measured in growth factor-treated renal primordia.
The UV/GFR of 0.12 demonstrates that developed primordia can
concentrate urine.14

Figure 1. Organ replacement therapies of the future.
Hemodialysis provides renal failure patients with GFRs that are about 10% of normal. Therefore, 6% of normal approximates a level of renal function that would be expected to preserve life. Indeed, life can be prolonged in otherwise anephric rat hosts by prior transplantation and ureteroureterostomy of a single renal primordium and survival can be extended if two primordia are connected to the host’s ureter. If the ureteroureterostomy is severed prior to removing all native renal mass from the host rat, survival is not prolonged. Therefore, metabolic functions of the transplant alone, are insufficient to preserve life in the absence of intact excretory function.

There are four theoretical reasons why the use of developing renal primordia for transplantation might be advantageous relative to mature kidneys in terms of generating a reduced cellular rejection response and obviating humoral rejection. First, if developing renal primordia are obtained at sufficiently early stage, antigen-presenting cells (APCs) that mediate ‘direct’ host recognition of alloantigen or xenoantigen are absent. Second, donor antigens such as MHC Class I and II are not expressed on developing renal primordia to the extent they are expressed on mature renal tissue. Third, the immune response to transplanted fetal renal tissue is ameliorated relative to the response to adult tissue. Fourth, transplanted renal primordia are supplied by blood vessels of host origin.

We transplanted renal primordia from E15 Lewis rat embryos across a concordant xenogeneic barrier into the mesentery of 10-week-old C57Bl/6J mice. In mice that receive immunosuppression, but not in its absence, transplanted rat renal primordia undergo differentiation and growth in situ.

We next transplanted E28 pig renal primordia into C57Bl/6J mice or Lewis rats. The differentiation of E28 pig renal primordia is comparable to that of E15 rat renal primordia. Pig renal primordia undergo growth and differentiation in immunosuppressed rodents, but not in the absence of host immune suppression. Figure 2 illustrates E28 pig renal primordia prior to transplantation (Fig. 2A and B) and seven weeks post-transplantation into immunosuppressed rat hosts (Fig. 2C–F). The maintenance immunosuppression regimen we used in rats was Tacrolimus 2 mg/kg daily intramuscularly post-implantation, one that could be tolerated in humans.

Pig renal primordia transplanted in rats grow to a size larger than native rat kidneys in rat hosts. This suggests that the hypoplasia may be more characteristic of transplanted rat renal primordia than of pig renal primordia. Hypoplasia can result from excessive cell death in metanephric blastema. Rapidly-dividing blastema cells in renal primordia could be placed at risk during the time of relative hypoperfusion that occurs between dissection from donor embryos and re-vascularization in situ. It may be that pig renal primordia, cells in which divide more slowly over a longer gestation period, are at reduced risk for apoptosis relative to rat primordia during the time of relative hypoperfusion. Our finding of more complete differentiation (kidneys larger than native rat kidneys) following pig-to-rat xenotransplantation relative to rat-to-rat allotransplantation is consistent with this possibility. Experiments currently in progress will determine whether transplantation of pig kidneys in rats or larger animals will prolong the recipient’s life long-term. If so, embryonic pig kidneys may prove a suitable source for replacement of human renal function.

**ORGANGENESIS OF ENDOCRINE PANCREAS**

Standard treatment for diabetes mellitus is insulin and diet. Such treatment is lifelong, painful and requires frequent monitoring of blood glucose. Tight control of glucose levels is impossible without inducing hypoglycemia. Even tight glucose control does not impact on long-term complications of diabetes.

Transplantation therapy for type 1 diabetes consists of human pancreas or islet transplantation, the latter being an experimental therapy. Transplantation can restore normal glucose tolerance and prevent complications. However, it requires immune suppression, in effect trading one disease (diabetes) for another (immune suppression).

There are insufficient human pancreas donor organs. Only about 1,000 pancreas transplants are performed per year in the USA for its 1.3 million type 1 diabetics. The shortage of donor organs effectively precludes transplantation for 20 million type 2 diabetics.

In that pigs are plentiful and because porcine insulin works well in humans, the pig has been suggested as a pancreas organ donor for human diabetics. The severity of humoral rejection effectively precludes their use as whole pancreas donors for non-human primates or humans. However, because they are vascularized by the host post-transplantation, isolated islets like other cell transplants are less susceptible to humoral rejection than pancreas transplants. Pig to human islet transplantation has been carried out without evidence for humoral-rejection. Unfortunately, even large numbers of transplanted porcine islets do not impact upon glucose control in human recipients. Recent experience with pig to non-human primate islet transplantations shows that sustained insulin independence can be achieved, but only through the use of immunosuppressive agents that are not approved for human use or would result in an unacceptable level of morbidity in humans.

It has been known since the 1970s that glucose tolerance in alloxan—or streptozotocin (STZ)—diabetic rats (a model for type 1 diabetes) can be normalized after isortransplantation of...
embryonic pancreatic primordia. Exocrine pancreas does not differentiate post-transplantation of pancreatic primordia obtained early during embryogenesis (E17).35-37 Thus, transplantation of pancreatic primordia from animal embryos represents an organogenesis solution for endocrine pancreas replacement without complications that accompany co-transplantation of exocrine pancreas such as digestion of host tissues from the action of pancreatic enzymes.30

In early experiments35,36 others transplanted embryonic pancreas beneath the renal capsule of hosts, a location from which insulin was released into the systemic venous circulation. It was shown subsequently that shunting venous flow from the systemic to portal systems post-transplantation improves diabetic control.37 This makes sense because normally, the pancreas secretes insulin directly into the portal vein from which it enters the liver directly.

We transplanted whole pancreatic primordia obtained from rat embryos just after organ formation begins (E12.5) into the mesentery of STZ-diabetic rats.38,39 On E12.5 the rat pancreas is undifferentiated and dorsal and ventral components remain separate.38 By four weeks post-transplantation of whole pancreatic primordia from E 12.5 Lewis rats into the mesentery of STZ-diabetic Lewis rats, the tissue has undergone differentiation and islets of Langerhans can be delineated amidst stroma. There is no differentiation of exocrine tissue.38,39 Abnormal glucose tolerance in STZ diabetic rat hosts is normalized within two to four weeks post-isotransplantation of pancreatic primordia as is the pattern of abnormal weight gain characteristic of diabetic animals.38,39

No host immunosuppression is required for isotransplantation of E12.5 rat embryonic pancreas. However engraftment following xenotransplantation from Lewis rat embryos to C57Bl/6J mice does require that hosts be immunosuppressed.38

Subsequently we showed that glucose tolerance can be normalized in adult STZ-diabetic Lewis rats38,40 or in diabetic ZDF rats, a model for human type 2 diabetes41 following transplantation of pancreatic primordia from E28 pig embryos into the mesentery. Formerly-diabetic rats have porcine insulin, but no rat insulin detectable in circulation. Transcripts for porcine insulin are present in islets of Langerhans can be delineated amidst stroma. There is no differentiation of exocrine tissue.38,39 Abnormal glucose tolerance in STZ diabetic rat hosts.

To examine the utility for transplantation of pig pancreatic primordia in a non-human primate model, we implanted embryonic pancreas from E28 pig embryos into the mesentery of STZ-diabetic male rhesus macaques.2 Long-term engraftment of pig β-cells within liver, pancreas and mesenteric lymph nodes post-transplantation was demonstrated by electron microscopy, positive immunohistochemistry for insulin, and positive RT-PCR and in-situ hybridization for porcine proinsulin mRNA.2 Insulin requirements were reduced in one macaque followed over 22 months post-transplantation and porcine insulin detected in plasma using sequential affinity chromatography, HPLC and mass spectrometry. Of potential importance for application of this transplantation technology to treatment of diabetes in humans and confirmatory of our previous findings in Lewis and ZDF rats, no host immunosuppression is required.2

Figure 3 shows photomicrographs originating from a mesenteric lymph node of a transplanted rhesus macaque.2 Sections in Figure 3A, C and E are stained with an anti-insulin antibody. Sections in Figure 3B, D and F are incubated with control serum. Sections of medullary sinus are delineated by arrows (Fig. 3A–D). Individual cells with β-cell morphology that stain positive (red) are delineated by arrowheads (Fig. 3E). No positive-staining cells are found in sections treated with control serum (Fig. 3B, D and F). Cells with morphology similar to positive cells in Figure 3E are delineated in Figure 3F (arrowheads). No insulin-positive cells are present in mesenteric lymph nodes of non-transplanted rhesus macaques.2

Shown in Figure 4 are sections of mesenteric lymph node from a diabetic rhesus macaque that had been transplanted more than a year previously with E28 pig pancreatic primordia. In situ hybridization was performed using pig proinsulin antisense (Fig. 4A and C) or sense (Fig. 4B and E) probe. Cells within medullary sinuses stain (red) with the antisense, (Fig. 4A and C) but not the sense (Fig. 4B and E) probe. Intravenous glucose infusion was performed in the rhesus macaque at 600 days following the original transplantation. No rhesus macaque insulin (<0.1 ng/ml) was detected in circulation at any time. Analysis of circulating insulin at five minutes post-infusion revealed porcine insulin in circulation (Fig. 5A and B). Rhesus macaque insulin only was detected in plasma from a non-fasting non-diabetic non-transplanted rhesus macaque (Fig. 5C and D). Only porcine insulin was detected in plasma obtained from pigs.2

Transplantation of embryonic pancreas offers theoretical advantages relative to transplantation of either pluripotent embryonic stem (ES) cells, or of fully differentiated (adult) pancreas or islets from adults or neonatal animals. Specifically: (1) Unlike ES cells, pancreatic primordia obtained at the proper time during
embryogenesis differentiate along defined organ-committed lines. There is no requirement to steer differentiation and no risk of teratoma formation; (2) Unlike the case for insulin-secreting cells derived from ES cells glucose-sensing and insulin-releasing functions are linked following in situ differentiation of transplanted pancreatic primordia; (3) The growth potential of cells within embryonic pancreas is enhanced relative to those in terminally-differentiated adult pancreas or islets. It is possible to restore glucose tolerance in a diabetic rat by transplanting a single pancreatic primordium; (4) Only endocrine tissue differentiates following transplantation of pancreatic primordia obtained sufficiently early during embryogenesis obviating problems of host tissue digestion by exocrine pancreatic components and (5) The cellular immune response to transplanted embryonic pancreas obtained early during embryogenesis is attenuated relative to that directed against organs obtained at later times.

Our finding that pig pancreatic primordia engraft long-term in non-immunosuppressed STZ diabetic rhesus macaques opens a window for their potential for their use in human diabetics. If applicable in humans, successful organogenesis of endocrine pancreas (or kidney) could provide in essence, an unlimited supply of donor organs. This would result in a paradigm shift in how the world thinks about organ replacement (Fig. 6):

(1) there will be no need to transport organs across long distances;
(2) transplantation can be done electively at a convenient time;
(3) transplantation can be offered to high-risk individuals and can be repeated as needed
(4) transplantation can be offered to patients currently not candidates including type 2 diabetics.

Dr. Hammerman: I think the observation that it is possible to transplant pig pancreatic primordia to non-human primates without an immunosuppression requirement is very important. The primordia engraft and secrete porcine insulin in the primate circulation. We can lower exogenous insulin requirements, but we have yet to normalize glucose tolerance in any transplanted primate. Until we do so it is premature to think about applying this technology in humans. Also, there is the issue of safety. We are about 2 ½ years out from our first pig-to-primate transplant. That animal is doing well. However, we have a long way to go and many additional transplants to perform before we can be sure that what we are doing is safe for humans.

Dr. Bob Karsh (Professor of Medicine, Washington University School of Medicine): You have told us about organogenesis of the kidney and endocrine pancreas. Is organogenesis applicable to other organs such as the liver?

Dr. Hammerman: In the 1980s two different groups attempted allotransplantation of liver and kidney from E15 rat embryos into adult rats. The renal primordia engrafted in non-immunosuppressed hosts, but the livers were rejected. Co-transplantation of E15 rat embryo liver and kidney resulted in rejection of both organs. The authors’ suggested that E15 rat livers, in contrast to kidneys, contain host-derived APCs that mediate direct antigen presentation resulting in rejection of liver or of liver and kidney transplanted at the same time. Hagihara et al. transplanted fragments of E18-19 fetal Wistar rat liver or E90 fetal swine liver into the omentum of non-immunosuppressed Wistar rats to which a lethal dose of D-galactosamine had been administered. The isografts formed nodules of hepatocytes at 72 hours post-transplantation, but the xenografts were necrotic by that time. Both isotransplantation and xenotransplantation improved survival.

Eventov-Friedman et al. transplanted minced embryonic pig liver in the spleen or beneath the renal capsule of nonobese diabetic (NOD) severe combined immunodeficient (SCID) mice. Both hepatocytes and bile ducts differentiated post-transplantation and porcine albumin was detected in the circulation of host mice. Transplantation of liver primordia obtained from embryos younger than E28 resulted in teratoma formation beneath the renal capsule.

Dr. Bharath M. Reddy (Instructor in Medicine, Washington University School of Medicine): It looks like you have had more success with pancreas organogenesis than with kidney organogenesis.

Dr. Hammerman: That’s one way to interpret our results. However, it’s probably too early to judge because it hard to know what the eventual application for either technology will be. As an example of an alternative way to use the renal organogenesis technology, Yokoo et al. implanted labeled human mesenchymal stem cells (hMSC) into the nephrogenic site of E11.5 rat embryos before the metanephric kidneys had formed. Following 48 hours of whole embryo culture, the metanephric primordia had formed in vitro and contained hMSC. Metanephroi were dissected out and transplanted into the omentum of uninephrectomized rats. Transplants enlarged over two weeks in non-immunosuppressed rat hosts, became vascularized by host vessels and contained hMSC-derived cells that were morphologically identical to resident renal cells. These findings suggest that transplanted renal primordia might be useful as a scaffold to generate a ‘humanized’ kidney.

Dr. Robert E. Schwartz (Resident in Medicine, Barnes-Jewish Hospital, Washington University School of Medicine): Have you seen any evidence for transmission of porcine endogenous retrovirus
Organogenesis Window Opens

Dr. Hammerman: It certainly is a concern. Several years ago Paradis et al. showed that despite persistent microchimerism (donor cells in human recipients of living pig tissue), PERV infection was not detected in human recipients. That is good news. Rood and Cooper have pointed out that transplantation of porcine islets into humans is being carried out all over the world. One hopes that mechanisms for informed consent and oversight are in place.

Dr. Rashmi S. Mullur (Instructor in Medicine, Washington University School of Medicine): How do the pig pancreatic cells get into lymph nodes?

Dr. Hammerman: Good question. I can only speculate. In contrast to islet formation that occurs within stroma following transplantation of rat pancreatic primordia into diabetic rats or mice, individual endocrine cells engraft in tissues following transplantation of E28 pig pancreatic primordia into the mesentery of diabetic rats and also following transplantation of E28 pig pancreatic primordia into the mesentery of STZ-diabetic rhesus macaques. During normal pancreatic organogenesis, individual endocrine cells first migrate away from primitive ducts prior to coalescing into islets. Migration and coalescence are guided by a number of cell and tissue adhesion molecules. We speculated that the failure of individual pig endocrine cells to coalesce into islets post-transplantation of E28 pig pancreatic primordia into rats, may result from the absence of adhesion molecules in rat interstitium that are recognized by pig endocrine cells. Therefore following transplantation of pancreatic primordia from pig-to-rat, the endocrine cells cannot re-aggregate to form islets. In contrast, rat endocrine cells recognize rat or mouse adhesion molecules and islets are formed albeit in the absence of exocrine tissue.

One explanation for our ability to transplant E28 pig pancreatic primordia without immunosuppression into rats or rhesus macaques may be that the absence of both exocrine tissue and islets results in a pattern of antigen expression that is not recognized as foreign by the host. An alternative explanation is host tolerance on the basis of chimerism as proposed by Abraham et al. to explain successful xenograftment of human pancreatic islet-derived progenitor cells in multiple tissues of non-immunosuppressed immunocompetent mice. Another is ‘T cell paralysis’ on the basis host exposure to antigen in the form of cells that express class II major histocompatibility complex II (MHC II) in the absence of a co-stimulatory signal. Of course, such explanations would require that our pig beta cells express MHC II or the swine equivalent, swine leukocyte antigen (SLA) II. Under some circumstances pig beta-cells do express SLA II.

Neural cell adhesion molecule (NCAM) is one of the regulars for endocrine cell aggregation during islet development. Crnic et al. showed that loss of NCAM function causes the formation of lymph node metastasis in a transgenic model of pancreatic...
β-cell carcinogenesis. Metastases were facilitated by upregulated pancreatic lymphangiogenesis possibly induced by the disaggregation of endocrine cells. Possibly, the failure of endocrine cells to aggregate following transplantation of E28 pig pancreatic primordia in the mesentery of rats or rhesus macaques induces a comparable lymphangiogenesis that permits migration of beta cells to regional lymph nodes. A state of chimerism results and tolerance is induced on the basis of SLA II expression on beta cells in the absence of co-stimulatory molecules. It may be that diabetic patients will be the ultimate beneficiaries of this rather fortuitous series of events that might render hosts tolerant post-transplantation of E28 pig pancreatic primordia.

Dr. Karsh: You have told us about what happens after transplantation of pancreas from E28 embryos. Have you tried transplanting pancreas from older embryos?

Dr. Hammerman: We have transplanted E28, E29 or E35 pig pancreatic primordia into non-immunosuppressed immunocompetent rats or non-human primates. Our experience in rats is that E35 primordia are rejected. However, either E28 or E29 primordia engraft in rats and E28 work best in terms of regularly normalizing glucose tolerance in STZ-diabetic rats. Given the absence of an immunosuppression requirement for engraftment of E28 pig pancreatic primordia in rats, we went directly to testing their efficacy in diabetic non-human primates.

Eventov Friedman et al. performed studies in which E21–E100 pig pancreatic primordia were transplanted under the kidney capsule of immunodeficient NOD-SCID mice. They found optimal growth potential as reflected by the highest levels of porcine pancreatic endocrine cells after transplantation of pig fetal renal primordia into rat. Transplantation of E42 pig pancreatic tissue and treated with an immunosuppression protocol consisting of CTLA4-Ig and anti-CD40 ligand attained normal glucose blood levels following transplantation of E42 primordia, eliminating the need for insulin.

Dr. Karsh: Was there teratoma formation following transplantation of embryonic pancreas?

Dr. Hammerman: In contrast to what they reported after transplantation of embryonic pig liver obtained prior to E28 in NOD-SCID mice, Eventov-Friedman found no teratoma formation following transplantation of pig pancreas obtained from embryos at any age. We have never detected teratomas following transplantation of embryonic rat or pig pancreas. Our transplanted rats have a normal rat life span of about two years and outlive non-transplanted STZ-diabetic animals.

Acknowledgements

Supported by George M. O’Brien Center DK079333 and grant 1-2005-110 from JDRF.

References